Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease

NCT02560298 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT02560298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02560298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 2
Overall status
Unknown status
Start date
August 23, 2016
Completion date
August 31, 2023
Enrollment
91 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anal basaloid carcinoma, anal canal cloacogenic carcinoma, anal squamous cell carcinoma, metastatic anal canal carcinoma, recurrent anal canal carcinoma, stage iiib anal canal cancer, stage iv anal canal cancer